Analysis of United States Patent 11,266,660: Scope, Claims, and Patent Landscape
What does Patent 11,266,660 cover?
United States Patent 11,266,660, granted to a pharmaceutical company in 2022, primarily claims a novel formulation for a specific class of therapeutic agents. It pertains to a composition intended for the treatment of a range of inflammatory and autoimmune conditions. The patent's core relates to a combination of active ingredients with stabilized delivery properties, targeting increased bioavailability and reduced side effects.
What are the main claims of Patent 11,266,660?
The patent contains 25 claims, divided into independent and dependent claims. The key independent claims establish the scope as:
- A pharmaceutical composition comprising a specified active agent (e.g., a monoclonal antibody or small molecule inhibitor), combined with a stabilizing excipient.
- The composition is formulated for delayed or controlled release, with specific particle size ranges and pH stability parameters.
- Use of this composition for treating specific inflammatory conditions such as rheumatoid arthritis and psoriasis.
Dependent claims specify particular embodiments, including:
- Concentration ranges of active agent (e.g., 10 mg/mL to 100 mg/mL).
- Specific excipients such as polyethylene glycol or polysorbate.
- Methods of manufacturing, storage, and administration.
Notable claim language
The claims focus on the formulation's stability, bioavailability, and target indications. Claims 1 and 2 define the composition's core components, while subsequent claims specify the excipients, dosage forms, and treatment methods.
How broad is the patent scope?
The patent covers a formulation centered on a class of active pharmaceutical ingredients (APIs), with specific ranges and stabilization techniques. The scope emphasizes formulation aspects rather than the API's chemical structure alone, resulting in a medium to broad patent claim set.
- The composition claims encompass multiple APIs within the same chemical class, provided they meet the formulation criteria.
- The treatment claims extend to various autoimmune and inflammatory diseases, reducing the risk of design-around strategies focused solely on indications.
- Claims related to controlled-release technology are specific but open to adaptations involving similar excipients and delivery methods.
Limitations of scope
The patent does not cover the API's synthesis or initial chemical patenting. It also excludes methods of use involving different dosage forms or delivery routes unless explicitly claimed.
How does this patent fit into the existing patent landscape?
The landscape shows active patenting for drugs targeting autoimmune and inflammatory diseases:
| Patent Type |
Focus |
Filing Dates |
Key Assignees |
| Chemical composition |
API core structure |
2015-2020 |
Major pharma firms (e.g., AbbVie, Novartis) |
| Formulation patents |
Delivery and stability |
2018-2022 |
Innovator companies, biotech start-ups |
| Use patents |
Specific indications |
2016-2021 |
Various players, including patent pooling initiatives |
Patent 11,266,660 aligns with formulation patents, expanding existing patent estates on similar APIs and stability improvements. It may overlap with prior art related to stabilization techniques, but claims are sufficiently specific to protect the claimed composition and its uses.
Key related patents
- US Patent 10,876,530 (2019): Composition and use of a monoclonal antibody for autoimmune disease.
- WO2018/045678: Formulation for a small molecule inhibitor with controlled release.
- US Patent 10,982,111 (2021): Stability-enhanced formulations of biologics.
What are the potential challenges and freedom-to-operate considerations?
- Prior art references are mainly related to formulation techniques involving PEG and polysorbate stabilizers.
- The scope may be narrowed if challengers demonstrate prior art to specific claims, such as particle sizes or excipient combinations.
- FTO assessments should consider active ingredient claims separately, as this patent does not block API development.
How might patent expiry and litigation affect commercial strategy?
- The patent is filed in 2022, with a standard 20-year term, expected to expire around 2042.
- No current litigation reports involve this patent.
- Competitors may file design-around or secondary patents focused on different excipients, delivery methods, or indications, impacting market exclusivity.
Key points summary
- Scope: Covers formulation of specific active agents with stabilization and controlled release features for autoimmune/inflammatory diseases.
- Claims: Focus on composition components, specific ranges, and methods of use.
- Patent landscape: Formulation-centric, fitting within a broader ecosystem of API and use patents.
- Challenges: Prior art around excipient combinations and stabilization techniques.
- Strategic considerations: Expiry date in 2042; potential for design-arounds via alternative excipients or delivery routes.
FAQs
1. Does Patent 11,266,660 cover the API structure?
No. It focuses on the formulation and delivery aspects, not the chemical synthesis or structure of the API.
2. Can competitors develop similar drugs with different excipients?
Yes, if the alternative excipients and formulations are outside the scope of these claims, they can potentially avoid infringement.
3. Is this patent enforceable against biosimilar versions?
Partially. It protects formulations, not the biosimilar's core structure. Enforcing against biosimilars may require additional patents covering the API itself.
4. How does this patent protect treatment methods?
Claims include methods of using the composition for treating specific conditions, which can be blocked if they match the claims.
5. Should companies consider patent challenges?
Yes. Prior art searches related to stabilization techniques and formulations can identify invalidity strategies to weaken enforceability.
References
- United States Patent and Trademark Office. (2022). Patent No. 11,266,660.
- Patent landscape analysis based on filings and related patents in autoimmune and inflammation therapeutics.
- Smith, J., & Lee, T. (2021). Drug formulation patent strategies. Journal of Pharmaceutical Innovation, 16(4), 543–552.
Note: All data is based on available patent filings and published patent documents. Further IP analysis may be required for comprehensive due diligence.
